The Retina Group of New York announced the availability of Eylea, the latest in a series of anti-VEGF medications for all patients with the wet form of age-related macular degeneration (AMD). The ...
Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...
If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated ...
Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The findings, ...
TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...
European Commission grants marketing approval for Eylea 8 mg to treat macular edema following RVO, including branch, central and hemiretinal vein occlusion: Berlin Monday, January ...
May 23 (Reuters) - German drugmaker Bayer (BAYGn.DE), opens new tab on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment ...
The FDA approved Regeneron’s Eylea to treat neovascular age-related macular degeneration, according to an OSN SuperSite report. According to Regeneron, the drug was under a priority review by the FDA, ...
REGN's Q4 report could hinge on Dupixent profit growth and strong Eylea HD uptake as legacy Eylea sales face competitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results